Exercise as Treatment for Hepatic Encephalopathy - Clinical Trials - Healia

Experimental models have shown that skeletal muscle is able to remove blood-borne ammonia, presumably by induction of an enzyme called glutamine synthetase. It is therefore conceivable that exercise can increase the metabolism of ammonia via glutamine synthetase, and therefore, improve hepatic encephalopathy.

Our hypothesis is that a regular exercise program can achieve improvement on hepatic encephalopathy on patients with liver failure and minimal or stage 1 (West-Haven) hepatic encephalopathy.

Patients will be randomized to a muscular and movement coordination rehabilitation program, to improve muscle mass and movement, as to increase ammonia metabolism.

Status: Recruiting (Phase 2).
Started on February 1st, 2007.
Ended on February 1st, 2009.
Enrollment: 30 subjects
Study Type: Interventional
Study Design:
- Treatment
- Randomized
- Open Label
- Placebo Control
- Parallel Assignment
- Safety/Efficacy Study
Conditions:
- Cirrhosis
- Hepatic Encephalopathy
  - Stage 1
- Minimal Hepatic Encephalopathy
Interventions:
- Other: Exercise rehabilitation program
- Dietary Supplement:
  - Nutritional therapy

Eligibility
Inclusion Criteria:
- Clinical diagnosis of cirrhosis
- Able to perform exercise

Exclusion Criteria:
- Cardiovascular complications (pulmonary hypertension, heart failure)
- Diabetes mellitus and microangiopathic complications
- Diabetes mellitus under insulin treatment
- Renal failure

Gender
- Both

Minimum Age
- 18 Years

Maximum Age
- 70 Years

Healthy Volunteers
- No
Portal hypertension with high risk for bleeding

Resources

Source: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Authority: Mexico: Universidad Nacional Autonoma de Mexico

Locations

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico
D.F.
14000
Mexico

Officials

• Sergio Ponce de Leon-Rosales, M.D. (Study Chair, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran / Universidad Nacional Autonoma de Mexico)

Sponsors

• Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (Lead Sponsor)
• Instituto Nacional de Cardiologia Ignacio Chavez (Collaborator)

References

None.

Links

None.

Date Verified
August 1st, 2007
First Received
August 16th, 2007
Last Changed
August 16th, 2007

Information obtained from ClinicalTrials.gov on July 15, 2008. Link to the current ClinicalTrials.gov record.